EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Botanical Sources: 9

Cissus Cissus quadrangularis L.

Also called: Cissus quadrangularis, veldt grape

Cissus quadrangularis is a climbing succulent of seasonally dry tropical regions of Africa, Arabia and South Asia. Trials have mostly given it by mouth, including an aqueous extract of the leaves and stems.

Category
Botanical
Part used
Stem and leaf (aqueous extract in weight trials)
Strongest evidence
C Limited
Native range
Native to tropical and southern Africa, Madagascar, the Arabian Peninsula and the Indian Subcontinent to Myanmar (POWO: "Tropical & S. Africa, Madagascar, Arabian Peninsula, Indian Subcontinent to Myanmar"); introduced elsewhere in the tropics
Reviewed
2026-10-30

Class 1 Well studied in people. A 2025 meta-analysis pooled 7 randomized controlled trials (354 participants) of Cissus quadrangularis in bone conditions; its Table 1 shows six tested oral Cissus alone against placebo, a drug regimen or no treatment. [1]

Fact-checked 2026-10-30 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

6 topics studied5 body areas · strongest grade C

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Cissus does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Cissus, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Bone biomarkers in fractures, dental bone procedures and osteopeniaCA 2025 meta-analysis of 7 RCTs (354 participants) found higher serum parathyroid hormone but no change in calcium, phosphorus or alkaline phosphatase; certainty of evidence was very low. [1]
Bone pain and fracture healingCA 2017 meta-analysis of nine studies (1,108 patients, all uses) found significant effects on bone pain; it rated evidence for bone fractures as low quality. [2]
Bone mineral density in postmenopausal women with osteopeniaCIn one 24-week RCT of 134 women, 1.2 or 1.6 g/day did not change bone mineral density versus placebo, though a bone-formation marker (P1NP) fell. [3]
Body weight and body fat in overweight adultsCIn an 8-week placebo-controlled RCT of 67 overweight adults, 300 mg/day of a stem-and-leaf extract lowered body fat and waist and hip size; the investigators' university funded the study. [4]
Body weight and blood lipids in overweight and obese adultsCIn a placebo-controlled trial of 168 overweight or obese adults (153 completed), 300 mg/day of the same extract reduced weight, body fat, total and LDL cholesterol, triglycerides and fasting glucose. [5]
Acute hemorrhoid symptomsXIn an RCT of 570 patients, 7 days of Cissus did no better than placebo or a flavonoid drug (micronized purified flavonoid fraction) for early symptoms. [6]

Main constituents: Alkaloids, flavonoids and triterpenoids, which the 2025 review says are thought to influence bone formation and resorption [1]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • Bone trials in the 2025 meta-analysis gave oral doses from 500 mg/day to 10 g/day for 4 to 24 weeks. [1]
  • 300 mg/day of an aqueous stem-and-leaf extract for 8 weeks (body fat trial). [4]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Interactions with medicines
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    1 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • The 2017 meta-analysis of nine studies reported no serious adverse effects. [2]
  • In the 570-patient hemorrhoid trial, no adverse events or blood chemistry changes were reported. [6]
  • In the 24-week osteopenia trial, adverse-event incidence did not differ between Cissus and placebo groups. [3]
Quality

Identity, quality and standardization

  • The 2025 review notes that the earlier 2017 meta-analysis pooled studies using different Cissus formulations, comparators and small samples, which may have made its estimates imprecise. [1]
  • For overweight and obesity, the 2017 meta-analysis could pool only combination products, so its pooled weight results describe combinations, not Cissus alone. [2]
Regulation

Regulatory status

  • US: by law, FDA does not approve dietary supplements or their labeling before they are marketed. [7]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Alkaloids, flavonoids and triterpenoids (thought to underlie effects on bone; not established) Alkaloids; flavonoids; triterpenoids [P1]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 1 entry naming Cissus quadrangularis (NDI 612, submitted 2009-09-14), a water extract of the leaves and stems. Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P3]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC evaluation of Cissus quadrangularis was found (IARC Monographs list of classifications, Volumes 1-142, checked 2026-10-29). [P5]
  • No NTP technical report on Cissus quadrangularis was found (NTP technical reports list checked 2026-10-29). [P6]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • No published information found in the sources checked.

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity test or examination of each dietary-ingredient component — US cGMP rule for dietary supplements: at least one appropriate test or examination must verify the identity of any component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)); exemption only through a petition FDA grants (111.75(a)(1)(ii)). [P4]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • No published information found in the sources checked.

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • No published information found in the sources checked.

Sources for this profile

  1. Na Takuathung M, Aisara J, Sawong S, Koonrungsesomboon N. The effects of Cissus quadrangularis on bone-related biomarkers in humans: a systematic review and meta-analysis. BMC Complement Med Ther 2025;25(1):286 (PMID 40707943; full text PMC12288206), 2025-07-24. pmc.ncbi.nlm.nih.gov
  2. Sawangjit R, Puttarak P, Saokaew S, Chaiyakunapruk N. Efficacy and safety of Cissus quadrangularis L. in clinical use: a systematic review and meta-analysis of randomized controlled trials. Phytother Res 2017;31(4):555-567 (PMID 28165166), 2017-04. pubmed.ncbi.nlm.nih.gov
  3. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  4. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
  5. IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1-142 (last updated 2026-07-23; checked 2026-10-29), 2026-07-23. monographs.iarc.who.int
  6. National Toxicology Program (NIEHS). Technical Reports list, TR-001 to TR-606 (checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
Sources

Sources

  1. Na Takuathung M, Aisara J, Sawong S, Koonrungsesomboon N. The effects of Cissus quadrangularis on bone-related biomarkers in humans: a systematic review and meta-analysis. BMC Complement Med Ther 2025;25(1):286 (PMID 40707943; full text PMC12288206), 2025-07-24. pmc.ncbi.nlm.nih.gov
  2. Sawangjit R, Puttarak P, Saokaew S, Chaiyakunapruk N. Efficacy and safety of Cissus quadrangularis L. in clinical use: a systematic review and meta-analysis of randomized controlled trials. Phytother Res 2017;31(4):555-567 (PMID 28165166), 2017-04. pubmed.ncbi.nlm.nih.gov
  3. Benjawan S, et al. The effect of Cissus quadrangularis L. on delaying bone loss in postmenopausal women with osteopenia: a randomized placebo-controlled trial. Phytomedicine 2022;101:154115 (PMID 35523116), 2022-07. pubmed.ncbi.nlm.nih.gov
  4. Nash R, Azantsa B, Kuate D, Singh H, Oben J. The use of a stem and leaf aqueous extract of Cissus quadrangularis (CQR-300) to reduce body fat and other components of metabolic syndrome in overweight participants. J Altern Complement Med 2019;25(1):98-106 (PMID 29912570), 2019-01. pubmed.ncbi.nlm.nih.gov
  5. Oben JE, et al. The effect of Cissus quadrangularis (CQR-300) and a Cissus formulation (CORE) on obesity and obesity-induced oxidative stress. Lipids Health Dis 2007;6:4 (PMID 17274828), 2007-02-04. pubmed.ncbi.nlm.nih.gov
  6. Panpimanmas S, et al. Experimental comparative study of the efficacy and side effects of Cissus quadrangularis L. (Vitaceae) to Daflon (Servier) and placebo in the treatment of acute hemorrhoids. J Med Assoc Thai 2010;93(12):1360-7 (PMID 21344797), 2010-12. pubmed.ncbi.nlm.nih.gov
  7. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
  8. Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Cissus quadrangularis L. (accessed 2026-10-29), 2026-10-29. powo.science.kew.org
  9. Vinoth K, Kumar SR. Morphological, molecular, and pharmacological review of veldt grape (Cissus quadrangularis L.): an underutilized medicinal plant. Front Plant Sci 2025;16:1586624 (PMID 40551764), 2025. pubmed.ncbi.nlm.nih.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.